AbbVie's Skyrizi takes home a win in late-stage Crohn's study, adding some heft to its expansion plans
AbbVie hasn’t been shy about its blockbuster ambitions for psoriasis med Skyrizi since launch, arguing it could go a long way to stanching the bleeding from Humira’s patent cliff. Now, the drugmaker is adding even more armor to Skyrizi’s chances at Crohn’s disease, a key indication in the drug’s expansion plans.
AbbVie’s Skyrizi dosed as a maintenance therapy hit its primary endpoints of clinical remission and endoscopic response after one year compared with an induction phase of the drug followed by withdrawal, according to topline data from the Phase III FORTIFY study presented Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.